FIG. 1.

KLF10 expression in epithelial, stromal cells, uterine eutopic endometrium, and endometriosis. A) Expression of KLF10 mRNA was assessed in two cell lines: Ishikawa, a well-differentiated endometrial adenocarcinoma cell line, and human endometrial stromal cells (Stromal). KLF10 was expressed in both cell lines utilizing B2M and HPRT1 as reference controls. To demonstrate KLF10 expression in each of these endometrial cell lines, lysate for RNA or protein extraction was obtained from one 10 cm cell culture dish of confluent cells. B, C) Using a tissue microarray (TMA) consisting of 306 samples of benign uterine endometrium during both the proliferative and secretory phases of the menstrual cycle, immunohistochemistry was performed for KLF10. KLF10 expression was significantly increased in the secretory phase of the menstrual cycle as compared to the proliferative phase (magnification ×200; inset ×400). Inset picture with arrow indicates increased staining. D) H scores were 59 ± 3 and 195 ± 8 in epithelial cells (Epi) and 37 ± 14 and 222 ± 4 in stromal cells (Str) during the proliferative and secretory phases (*P < 0.05 as shown). E, F) KLF10 expression was also evaluated in 28 paired samples of eutopic endometrium and ectopic endometrial implants by immunohistochemistry. Representative samples are shown. KLF10 was expressed in nuclei and cytoplasm of epithelial and stromal cells in both eutopic endometrium as well as in endometriotic implants. KLF10 expression was decreased in endometriotic implants compared to eutopic endometrium (magnification ×200; inset ×400). Inset picture with arrow indicates increased staining. G) Corresponding H scores were: 161 ± 15 and 42 ± 6 in epithelial cells and 179 ± 24 and 37 ± 3 in stromal cells in eutopic endometrium and endometriosis, respectively (*P < 0.05 as shown).